Applying real-world evidence in drug approvals: an interview with Murtuza Bharmal

Written by The Evidence Base

In this interview, Murtuza Bharmal discusses how Merck KGaA, Darmstadt, Germany utilized real-world evidence in the approval process for avelumab. Murtuza is a member of The Evidence Base’s Expert Panel. Up until 2017, no approved treatments existed for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and deadly form of skin cancer. Since then, avelumab has been approved by the FDA, EMA and many other health authorities across the world for this indication, and more recently, pembrolizumab has been approved by FDA, with several other immune checkpoint inhibitors in clinical trials for mMCC. We spoke to Murtuza Bharmal,...

To view this content, please register now for access

It's completely free